A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors - Cho, Byoung Chul; Han, Ji-Youn; Kim, Sang-We; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok; Shim, Byoung Yong; Kim, Jin-Soo; et al. (Journal of Thoracic Oncology, 2022)